JPWO2022221335A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022221335A5 JPWO2022221335A5 JP2023563061A JP2023563061A JPWO2022221335A5 JP WO2022221335 A5 JPWO2022221335 A5 JP WO2022221335A5 JP 2023563061 A JP2023563061 A JP 2023563061A JP 2023563061 A JP2023563061 A JP 2023563061A JP WO2022221335 A5 JPWO2022221335 A5 JP WO2022221335A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- vaccine
- virus
- antigenic polypeptide
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174463P | 2021-04-13 | 2021-04-13 | |
| US63/174,463 | 2021-04-13 | ||
| US202163175011P | 2021-04-14 | 2021-04-14 | |
| US63/175,011 | 2021-04-14 | ||
| US202163241959P | 2021-09-08 | 2021-09-08 | |
| US63/241,959 | 2021-09-08 | ||
| US202263322121P | 2022-03-21 | 2022-03-21 | |
| US63/322,121 | 2022-03-21 | ||
| PCT/US2022/024497 WO2022221335A1 (en) | 2021-04-13 | 2022-04-12 | Respiratory virus combination vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514182A JP2024514182A (ja) | 2024-03-28 |
| JPWO2022221335A5 true JPWO2022221335A5 (https=) | 2025-04-17 |
| JP2024514182A5 JP2024514182A5 (https=) | 2025-04-17 |
Family
ID=81449216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563061A Pending JP2024514182A (ja) | 2021-04-13 | 2022-04-12 | 呼吸器ウイルス組み合わせワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240216500A1 (https=) |
| EP (1) | EP4322993A1 (https=) |
| JP (1) | JP2024514182A (https=) |
| AU (1) | AU2022258335A1 (https=) |
| WO (1) | WO2022221335A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN120435314A (zh) * | 2022-12-29 | 2025-08-05 | 波普瓦克斯私人有限公司 | 多靶疫苗和治疗剂 |
| JP2026503735A (ja) * | 2023-01-31 | 2026-01-29 | アークトゥルス セラピューティクス， インコーポレイテッド | 四価インフルエンザワクチンのための方法及び組成物 |
| CN121419787A (zh) * | 2023-06-28 | 2026-01-27 | 赛诺菲巴斯德有限公司 | 多价流感mRNA疫苗 |
| WO2025186719A1 (en) * | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026003577A1 (en) * | 2024-06-25 | 2026-01-02 | Popvax Private Limited | Multisubunit hepacivirus vaccines and therapeutics |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| US20090104226A1 (en) * | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8278063B2 (en) | 2007-06-29 | 2012-10-02 | Commonwealth Scientific And Industrial Research Organisation | Methods for degrading toxic compounds |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| KR20130112950A (ko) * | 2011-02-04 | 2013-10-14 | 조에티스 엘엘씨 | 개 호흡기 복합 질환용 조성물 |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| TW201729835A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| BR112019008481A2 (pt) * | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| MX2022015132A (es) * | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
-
2022
- 2022-04-12 WO PCT/US2022/024497 patent/WO2022221335A1/en not_active Ceased
- 2022-04-12 JP JP2023563061A patent/JP2024514182A/ja active Pending
- 2022-04-12 EP EP22720218.1A patent/EP4322993A1/en active Pending
- 2022-04-12 AU AU2022258335A patent/AU2022258335A1/en active Pending
- 2022-04-12 US US18/555,087 patent/US20240216500A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022221335A5 (https=) | ||
| JPWO2022221440A5 (https=) | ||
| JPWO2022155524A5 (https=) | ||
| DE112021000012C9 (de) | Coronavirus-Vakzine | |
| Melero et al. | The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals | |
| Verwey et al. | Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus: C. Verwey, SA Madhi | |
| TW202233232A (zh) | 遞送mRNA疫苗的脂質奈米顆粒 | |
| JPWO2022155530A5 (https=) | ||
| JP7817257B2 (ja) | ｍＲＮＡワクチンを送達するための脂質ナノ粒子 | |
| TW202206096A (zh) | 冠狀病毒疫苗 | |
| TW202333780A (zh) | 冠狀病毒疫苗 | |
| Fotouhi et al. | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus | |
| Falsey | Current management of parainfluenza pneumonitis in immunocompromised patients: a review | |
| RU2014104094A (ru) | Катионные эмульсии масло-в-воде | |
| JPH11500409A (ja) | ワクチン組成物用アジュバント | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| Wang et al. | Self-assembly M2e-based peptide nanovaccine confers broad protection against influenza viruses | |
| JPWO2021155243A5 (https=) | ||
| JP2014522841A5 (https=) | ||
| Adu-Gyamfi et al. | Flexibility of the head-stalk linker domain of paramyxovirus HN glycoprotein is essential for triggering virus fusion | |
| US12208136B2 (en) | Coronavirus vaccine | |
| JP2002532435A (ja) | Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物 | |
| WO2024191860A2 (en) | Nucleic acid influenza vaccines and respiratory virus combination vaccines | |
| JP2024015475A (ja) | コロナウイルスワクチン | |
| KR20250088606A (ko) | 호흡기 세포융합 바이러스 백신 및 이의 제조 방법과 용도 |